Rituximab biosimilar - Celltrion

Drug Profile

Rituximab biosimilar - Celltrion

Alternative Names: CT-P10; Truxima

Latest Information Update: 06 Mar 2017

Price : $50

At a glance

  • Originator Celltrion
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Microscopic polyangiitis; Non-Hodgkin's lymphoma; Rheumatoid arthritis; Wegener's granulomatosis

Most Recent Events

  • 22 Feb 2017 Registered for Chronic lymphocytic leukaemia (First-line therapy, Combination therapy) in Liechtenstein, Iceland, Norway, European Union (IV)
  • 22 Feb 2017 Registered for Diffuse large B cell lymphoma (Combination therapy) in European Union, Liechtenstein, Iceland, Norway (IV)
  • 22 Feb 2017 Registered for Chronic lymphocytic leukaemia Combination therapy, Second-line therapy or greater) in European Union, Iceland, Liechtenstein and Norway (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top